As an R&D-oriented organization, Takara Bio is dedicated to the development of biotechnology-related products and technologies. In an industry dependent on constant technical innovation, our management policy is to conduct R&D aggressively while improving our profitability, return the profit to our shareholders. To achieve this, we are striving to expedite our decision-making and to improve our business efficiency.

Our board of directors consists of nine members who meet whenever necessary in addition to the regular monthly board meetings. The board makes decisions on important issues concerning the management of the Company and its management policies as well as overseeing execution of the company’s business. One of our directors, Masayori Inouye, is also a professor of the Biochemistry Department at the New Jersey University of Medicine and Dentistry.

The Company has adopted an auditing system, and two of our three auditors are external to the company.

Our parent company is Takara Holdings Inc., which owns 71.1% of voting rights as of the end of March 2007. Takara Holdings’ policy in managing its group companies is to seek to maximize the corporate value of the whole group while enabling each and every member corporation of the Group to maintain its uniqueness and independence. Since our business of biotechnology requires highly advanced expertise and quick decision making, we are especially unique and independent in the Group. While we report the decisions made at our board meetings and other issues to the parent company, no prior approval is required in order to execute our decisions.

Corporate Governance System